Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

iSpecimen Inc.

NASDAQ: ISPC · Industrial Applications and Services · 5 alerts · CIK 1558569

Share price
$0.6049Close, Nov 16
Market cap
$1.52M
Shares outstanding
2.52MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All iSpecimen Inc. filings on SEC EDGAR ↗

6:32 AM ET 10-Q
Financial Results

iSpecimen Q3 2026 Results: Net Loss of $2.21M, Loss Narrows

For the nine months ended September 30, 2026, iSpecimen Inc. reported a net loss of $5.85 million on revenue of $551,983, a significant decrease from $1.88 million in revenue for the same period in 2025. The company strengthened its balance sheet through PIPE financings totaling $7.5 million and executed a 1-for-40 reverse stock split in April 2026.

Key figure
Net loss $2.21M
5:16 PM ET 8-K
Capital Raise

iSpecimen Capital Raise

iSpecimen Inc. entered into a securities purchase agreement with accredited investors for a private placement of 500 shares of Series D Convertible Preferred Stock at $800 per share. The offering generated gross proceeds of $400,000, which the company intends to use for working capital and general corporate purposes. E.F. Hutton & Co. served as the exclusive placement agent for the transaction.

Counterparty
E.F. Hutton & Co.
5:01 PM ET 8-K
M&A Deal

iSpecimen Signs $4.5M M&A Deal with Foldlab AI Ltd.

iSpecimen Inc. completed the acquisition of AI software assets from Foldlab AI Ltd. for an aggregate purchase price of $4.5 million, consisting of $750,000 in cash, $1.25 million in milestone payments, and $2.5 million in common stock. The acquired assets include a Disease-Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model, marking the company's entry into AI-powered drug discovery.

Value
$4.5M
Counterparty
Foldlab AI Ltd.
5:01 PM ET 8-K
Reverse Stock Split

iSpecimen Reverse Stock Split

iSpecimen Inc. stockholders approved an amendment to the company's Certificate of Incorporation to effect a reverse stock split. The approved ratio range is between 1-for-10 and 1-for-100, with the final ratio to be determined by the Board of Directors.

4:31 PM ET 8-K
M&A Deal

iSpecimen M&A Deal with Foldlab AI Ltd.

iSpecimen Inc. stockholders approved the acquisition of assets from Foldlab AI Ltd., which includes the issuance of common stock as partial consideration. The company also received approval for potential future equity issuances exceeding 19.99% of outstanding shares under Nasdaq rules, while the vote on a proposed reverse stock split was adjourned to October 30, 2026.

Counterparty
Foldlab AI Ltd.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.